Voyager Therapeutics (NASDAQ:VYGR) Posts Earnings Results, Beats Expectations By $0.01 EPS

Voyager Therapeutics (NASDAQ:VYGR) posted its earnings results on Thursday. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.01, FiscalAI reports. The firm had revenue of $0.61 million for the quarter, compared to the consensus estimate of $6.35 million. Voyager Therapeutics had a negative net margin of 312.63% and a negative return on equity of 57.92%.

Voyager Therapeutics Stock Performance

Shares of VYGR stock opened at $1.72 on Friday. Voyager Therapeutics has a 52-week low of $1.68 and a 52-week high of $5.48. The firm has a market capitalization of $105.99 million, a P/E ratio of -0.96 and a beta of 1.20. The stock has a 50 day moving average price of $2.58 and a 200 day moving average price of $3.42.

Wall Street Analysts Forecast Growth

VYGR has been the subject of several analyst reports. HC Wainwright reaffirmed a “buy” rating on shares of Voyager Therapeutics in a research note on Thursday, August 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Voyager Therapeutics in a research report on Friday, October 9th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $16.50.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a biotechnology company focused on developing gene therapies for neurological diseases. The company aims to address conditions affecting the central nervous system by using adeno-associated virus (AAV) gene-delivery technologies to deliver therapeutic genes to targeted areas of the brain and nervous system.

Voyager’s research platform, known as TRACER, is designed to identify AAV capsids with improved ability to cross the blood-brain barrier and reach the central nervous system.